The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.
Study Type
OBSERVATIONAL
Enrollment
225
Occurrence Measured in Time of an Image Showing Positive for M1 (Metastatic Disease) at Baseline to Registration
The primary endpoint for the study will be the occurrence of an imaging study at baseline that is positive for M1 (yes or no) among all patients in the primary analysis population.The primary analysis population consists of patients who had a current diagnosis of having non metastatic (M0) disease at baseline. These patients underwent imaging scans at baseline and were assessed for metastatic (M1) versus non metastatic (M0) disease.
Time frame: Each enrolled subject will be evaluated at baseline for the occurrence of metastatic disease by positive imaging scan.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
Urological Associate of Southern Arizona
Tucson, Arizona, United States
Sequoia Urology Center
Atherton, California, United States
Prostate Oncology Specialist, Inc.
Marina del Rey, California, United States
Sutter Medical Group
Sacramento, California, United States
Genesis Research
San Diego, California, United States
Urology Associates of San Luis Obispo
Templeton, California, United States
The Urology Center of Colorado
Denver, Colorado, United States
Advanced Urology, P.C
Parker, Colorado, United States
Howard University Hospital
Washington D.C., District of Columbia, United States
...and 48 more locations